The HP-3D9 monoclonal antibody specifically binds to CD94 which is also known as KP43. CD94 is expressed on the cell surface as a ~70 kDa, disulfide-linked, type II transmembrane glycoprotein dimer. It is encoded by KLRD1 (Killer cell lectin like receptor D1) which belongs to the C-type lectin superfamily. CD94 is expressed on natural killer (NK) cells, especially activated NK cells. It is also expressed on γ/δ TCR+ T lymphocytes, NK-T cells, and on some CD8+CD56+ α/β TCR+ cells. CD94 associates with various NKG2 receptors to form receptors for HLA class I molecules and plays a role in regulating cellular adhesion and activation. The HP-3D9 antibody can reportedly inhibit the cytolytic activity of activated NK cells.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system or other oligo-dT-based capture systems. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.